The Fruiting Bodies, Submerged Culture Biomass, and Acidic Polysaccharide Glucuronoxylomannan of Yellow Brain Mushroom Tremella mesenterica Modulate the Immunity of Peripheral Blood Leukocytes and Splenocytes in Rats with Impaired Glucose Tolerance

10.4103/2225-4110.124347

Tai-Hao Hsu；Chien-Hsing Lee；Fang-Yi Lin；Solomon P. Wasser；Hui-Chen Lo

Cytokines ； Diabetes ； Immunocytes ； Polysacchardies ； Tremella mesenterica

Journal of Traditional and Complementary Medicine

4卷1期（2014 / 01 / 01）

56 - 63

英文

The prevalence of diabetes mellitus (DM), a chronic disease with hyperglycemia and impaired immune function, is increasing worldwide. Progression from impaired glucose tolerance (IGT) to type 2 DM has recently become a target for early intervention. The fruiting bodies (FB) and submerged culture mycelium (CM) of Tremella mesenterica, an edible and medicinal mushroom, have been demonstrated to have antihyperglycemic and immunomodulatory activities in type 1 DM rats. Herein, we investigated the effects of acidic polysaccharide glucuronoxylomannan (GX) extracted from CM on the immunocyte responses. Male Wistar rats were injected with streptozotocin (65 mg/kg) plus nicotinamide (200 mg/kg) for the induction of IGT, and gavaged daily with vehicle, FB, CM, or GX (1 g/kg/day). Rats injected with saline and gavaged vehicle were used as controls. Two weeks later, peripheral blood leukocytes (PBLs) and splenocytes were collected. Ingestion of FB, CM, and GX significantly decreased blood glucose levels in the postprandial period and in oral glucose tolerance test, and partially reversed T-splenocytic proliferation in IGT rats. CM significantly decreased T‑helper lymphocytes in the PBLs and B-splenocytes. In addition, FB, CM, and GX significantly reversed the IGT-induced decreases in tumor necrosis factor-α production; GX significantly increased interleukin-6 production in T-lymphocytes in the PBLs and splenocytes; and CM and GX significantly reversed IGT-induced decrease in interferon-γ production in T-lymphocytes in the spleen. In conclusion, FB, CM, and acidic polysaccharide GX of T. mesenterica may increase T-cell immunity via the elevation of proinflammatory and T-helper cytokine production in rats with impaired glucose tolerance.

1. World Health Organization. Available from: http://www.who.int/mediacentre/factsheets/fs312/en/[Last accessed in 2013 Jul].
2. American Diabetes Association. Available from: http://www.diabetes.org/diabetes‑basics/prevention/pre‑diabetes/?loc=DropDownDB‑prediabetes [Last accessed on 2013 Jul].
3. Ceriello, A(2004).Impaired glucose tolerance and cardiovascular disease: The possible role of post‑prandial hyperglycemia.Am Heart J,147,803-807.
4. Chang, FY,Shaio, MF(1995).Decreased cell‑mediated immunity in patients with non‑insulin‑dependent diabetes mellitus.Diabetes Res Clin Pract,28,137-146.
5. Chen, H,Wen, F,Zhang, X,Su, SB(2012).Expression of T‑helper‑associated cytokines in patients with type 2 diabetes mellitus with retinopathy.Mol Vis,18,219-226.
6. Choi, KM,Lee, J,Lee, KW,Seo, JA,Oh, JH,Kim, SG(2004).Comparison of serum concentrations of C‑reactive protein, TNF‑alpha, and interleukin 6 between elderly Korean women with normal and impaired glucose tolerance.Diabetes Res Clin Pract,64,99-106.
7. Cui, JY,Lin, ZB.(1997).Effects of Tremella polysaccharide on cytoplasmic free calcium concentration in murine splenocytes.Yao Xue Xue Bao,32,561-564.
8. Danaei, G,Finucane, MM,Lu, Y,Singh, GM,Cowan, MJ,Paciorek, CJ(2011).National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: Systematic analysis of health examination surveys and epidemiological studies with 370 country‑years and 2.7 million participants.Lancet,378,31-40.
9. Daoud, AK,Tayyar, MA,Fouda, IM,Harfeil, NA(2009).Effects of diabetes mellitus vs. in vitro hyperglycemia on select immune cell functions.J Immunotoxicol,6,36-41.
10. Esposito, K,Nappo, F,Marfella, R,Giugliano, G,Giugliano, F,Ciotola, M(2002).Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: Role of oxidative stress.Circulation,106,2067-2072.
11. Gao, QP,Jiang, RZ,Chen, HQ,Jensen, E,Seljelid, R(1996).Characterization and cytokine stimulating activities of heteroglycans from Tremella fuciformis.Planta Med,62,297-302.
12. Hu, FB,Meigs, JB,Li, TY,Rifai, N,Manson, JE(2004).Inflammatory markers and risk of developing type 2 diabetes in women.Diabetes,53,693-700.
13. Jagannathan‑Bogdan, M,McDonnell, ME,Shin, H,Rehman, Q,Hasturk, H,Apovian, CM(2011).Elevated proinflammatory cytokine production by a skewed T cell compartment requires monocytes and promotes inflammation in type 2 diabetes.J Immunol,186,1162-1172.
14. Jeong, SC,Koyyalamudi, SR,Hughes, J,Khoo, C,Bailey, T,Marripudi, K(2013).Antioxidant and immunomodulating activities of exo‑and endopolysaccharide fractions from submerged mycelia cultures of culinary‑medicinal mushrooms.Int J Med Mushrooms,15,251-266.
15. Kiho, T,Kochi, M,Usui, S,Hirano, K,Aizawa, K,Inakuma, T(2001).Antidiabetic effect of an acidic polysaccharide (TAP) from Tremella aurantia and its degradation product (TAP‑H).Biol Pharm Bull,24,1400-1403.
16. Lechleitner, M,Herold, M,Dzien‑Bischinger, C,Hoppichler, F,Dzien, A(2002).Tumour necrosis factor‑alpha plasma levels in elderly patients with Type 2 diabetes mellitus‑observations over 2 years.Diabet Med,19,949-953.
17. Lo, HC,Hsu, TH,Lin, FY,Wasser, SP,Chen, YH,Lee, CH(2012).Effects of yellow brain culinary‑medicinal mushroom, Tremella mesenterica Ritz.:Fr. (higher Basidiomycetes), on immune function in normal and type 1 diabetic rats.Int J Med Mushrooms,14,447-457.
18. Lo, HC,Tsai, FA,Wasser, SP,Yang, JG,Huang, BM(2006).Effects of ingested fruiting bodies, submerged culture biomass, and acidic polysaccharide glucuronoxylomannan of Tremella mesenterica Retz.:Fr. on glycemic responses in normal and diabetic rats.Life Sci,78,1957-1966.
19. Lo, HC,Wasser, SP(2011).Medicinal mushrooms for glycemic control in diabetes mellitus: History, current status, future perspectives, and unsolved problems.Int J Med Mushrooms,13,401-426.
20. Lo, HC,Yang, JG,Liu, BC,Chen, YW,Huang, YL,Poon, SL(2004).The effects of Tremella aurantia on testosterone and corticosterone productions in normal and diabetic rats.Arch Androl,50,395-404.
21. Ma, L,Lin, ZB(1992).Effect of Tremella polysaccharide on IL‑2 production by mouse splenocytes.Yao Xue Xue Bao,27,1-4.
22. Masiello, P,Broca, C,Gross, R,Roye, M,Manteghetti, M,Hillaire‑Buys, D(1998).Experimental NIDDM: development of a new model in adult rats administered streptozotocin and nicotinamide.Diabetes,47,224-229.
23. Müller, S,Martin, S,Koenig, W,Hanifi‑Moghaddam, P,Rathmann, W,Haastert, B(2002).Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co‑regulated acute‑phase proteins but not TNF‑alpha or its receptors.Diabetologia,45,805-812.
24. Pickup, JC,Crook, MA(1998).Is type II diabetes mellitus a disease of the innate immune system?.Diabetologia,41,1241-1248.
25. Reshetnikov, SV,Wasser, SP,Duckman, I,Tsukor, K.(2001).Regulation of growth and biosynthetic activity of the medicinal jelly mushroom Tremella mesenterica Retz.: Fr. pure culture.Int J Med Mushrooms,3,45-51.
26. Samaras, K,Viardot, A,Lee, PN,Jenkins, A,Botelho, NK,Bakopanos, A(2013).Reduced arterial stiffness after weight loss in obese type 2 diabetes and impaired glucose tolerance: The role of immune cell activation and insulin resistance.Diab Vasc Dis Res,10,40-48.
27. Schmidt, MI,Duncan, BB,Sharrett, AR,Lindberg, G,Savage, PJ,Offenbacher, S(1999).Markers of inflammation and prediction of diabetes mellitus in adults (atherosclerosis risk in communities study): A cohort study.Lancet,15,1649-1652.
28. Spranger, J,Kroke, A,Mohlig, M,Hoffmann, K,Bergmann, MM,Ristow, M(2003).Inflammatory cytokines and the risk to develop type 2 diabetes: Results of the prospective population‑based European Prospective Investigation into Cancer and Nutrition (EPIC)‑Potsdam study.Diabetes,52,812-817.
29. Ukai, S,Kiriki, H,Nagai, K,Kiho, T(1992).Synthesis and antitumor activities of conjugates of mitomycin C‑polysaccharide from Tremella fuciformis.Yakugaku Zasshi,112,663-668.
30. WHO(2010).Global status report on NCDs 2010.